The Future of Peer Review in Scientific Manuscripts: Embracing Artificial Intelligence

By Staff Writer

May 28, 2024

Introduction

The future of peer review in scientific publishing should include artificial intelligence (AI). Large-language models, incorporating in-context learning, could assist editors in triaging manuscripts. Numerous questions have emerged over decades concerning peer review. Is it effective in detecting fabrication, falsification, image manipulation, or adherence to reporting guidelines? Can AI be fair, or subject to bias? Is it efficient, or increasingly labour-intensive without compensation? Given these challenges, AI should and will be increasingly used to assist in peer review.

Effectiveness of AI in Peer Review

Peer review is crucial for maintaining the quality of scientific publications. However, human reviewers often struggle to detect issues like data fabrication, falsification, and image manipulation. AI could be more effective at identifying these problems. For instance, large-language models could be trained to spot inconsistencies in data and adherence to reporting guidelines. A study by Liang et al. assessed the agreement between human reviewers and GPT-4 on 3096 manuscripts submitted to 15 Nature journals. They found a 30.1% overlap in comments, which is comparable to the 28.6% overlap between two human reviewers. This suggests that AI can provide valuable insights, potentially even more so than human reviewers.

Fairness in Peer Review

Bias in peer review is a well-documented problem. Various forms of peer review, such as open, single-blind, and double-blind, aim to mitigate bias. However, these methods are not foolproof. For example, a study found that manuscripts from authors with Nobel prizes were less likely to be rejected compared to those from unknown authors. AI could help reduce bias in peer review. Algorithms can be designed to evaluate manuscripts based solely on their content, without considering the authors’ identities or affiliations. This could lead to a fairer assessment process and reduce the influence of factors like language proficiency and institutional reputation.

Efficiency in Peer Review

The number of scientific publications has increased by 47% between 2016 and 2022, reaching 2.82 million manuscripts per year. This surge has overwhelmed editors and peer reviewers, leading to a higher rejection rate without external review. AI can help alleviate this burden by initially screening manuscripts and providing a summary of their quality. AI can also speed up the review process. For example, a recent study found that 57.4% of investigators in AI and computational biology found GPT-4’s feedback helpful, and 82.4% found it more helpful than some human reviewers. This indicates that AI can provide timely and valuable feedback, enhancing the efficiency of the review process.

The Future of AI in Peer Review

While AI shows promise, it is not yet ready to replace human reviewers entirely. Current systems need more data to improve their accuracy and reliability. However, AI can complement human reviewers by providing initial assessments and identifying potential issues. One concern is the confidentiality of manuscripts. Large-language models extract data from numerous published works, which could compromise the confidentiality of the reviewed manuscripts. A possible solution is to limit AI’s training data to the journal’s database or open-access articles.

In the future, AI could be used to scan all submissions and provide a quality summary for editors. This will help editors decide whether to proceed with external peer review. Embracing AI in peer review is inevitable, and the focus should be on evaluating its effectiveness and reassuring authors about the fairness of the process.

Conclusion

AI has the potential to address many challenges in the peer review process, including effectiveness, fairness, and efficiency. While it is not yet ready to replace human reviewers, it can significantly enhance the review process. As AI technology matures, it will likely play an increasingly important role in scientific publishing.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.